Clincosm LogoSign in Get a demo

Genetic Susceptibility to Kidney Cancer

Sponsor
Baylor College of Medicine (Other)
Overall Status
Terminated
CT.gov ID
NCT00854022
Collaborator
M.D. Anderson Cancer Center (Other)
6
Enrollment
1
Location
56
Duration (Months)
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will further the understanding of the genetic events leading to the development of RCC.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and eventually provide a means of identifying a subgroup of individuals who are most likely to develop RCC. Such individuals may then be targeted for intervention programs such as chemoprevention or dietary modification.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    6 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Genetic Susceptibility to Renal Cell Carcinoma
    Study Start Date :
    Jul 1, 2008
    Actual Primary Completion Date :
    Mar 1, 2013
    Actual Study Completion Date :
    Mar 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    Healthy

    Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
    RCC

    Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.

    Outcome Measures

    Primary Outcome Measures

    1. To identify interindividual differences in inherited genetic instability [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients of any ethnicity or sex, who have a been diagnosed with possible Renal Cell Carcinoma within the past year.
    Exclusion Criteria:

    • Must not have received chemotherapy, biological therapy or radiation therapy in the 6 months preceding enrollment will

    • Must not have had RCC, or metastatic RCC,

    • Must not have had a renal transplantation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 MD Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • Baylor College of Medicine
    • M.D. Anderson Cancer Center

    Investigators

    • Principal Investigator: Seth P. Lerner, MD, Baylor College of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Seth Lerner, Professor, Baylor College of Medicine
    ClinicalTrials.gov Identifier:
    NCT00854022
    Other Study ID Numbers:
    • H-17150
    First Posted:
    Mar 2, 2009
    Last Update Posted:
    Feb 25, 2020
    Last Verified:
    Feb 1, 2020
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Renal Cell
    Genetic Predisposition to Disease

    Study Results

    No Results Posted as of Feb 25, 2020